Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.

Gimenez-Xavier P, Pros E, Aza A, Moran S, Tonda R, Esteve-Codina A, Dabad M, Sanchez-Cespedes M.

Oncotarget. 2018 Jul 31;9(59):31549-31558. doi: 10.18632/oncotarget.25862. eCollection 2018 Jul 31.

2.

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.

Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Cancer Res. 2018 Sep 15;24(18):4579-4587. doi: 10.1158/1078-0432.CCR-18-0267. Epub 2018 Jun 13.

PMID:
29898990
3.

Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.

Saigi M, McLeer-Florin A, Pros E, Nadal E, Brambilla E, Sanchez-Cespedes M.

Clin Transl Oncol. 2018 Jul;20(7):881-888. doi: 10.1007/s12094-017-1799-7. Epub 2017 Nov 14.

PMID:
29139039
4.

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.

Gimenez-Xavier P, Pros E, Bonastre E, Moran S, Aza A, Graña O, Gomez-Lopez G, Derdak S, Dabad M, Esteve-Codina A, Hernandez Mora JR, Salinas-Chaparro D, Esteller M, Pisano D, Sanchez-Cespedes M.

Mol Cancer Ther. 2017 Jul;16(7):1366-1376. doi: 10.1158/1535-7163.MCT-17-0104. Epub 2017 Apr 10.

5.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

6.

MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1.

Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.

Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799. Epub 2013 Dec 20.

7.

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.

Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M.

Int J Cancer. 2013 Aug 15;133(4):898-907. doi: 10.1002/ijc.28090. Epub 2013 Mar 9.

8.

Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.

Menéndez M, Castellsagué J, Mirete M, Pros E, Feliubadaló L, Osorio A, Calaf M, Tornero E, del Valle J, Fernández-Rodríguez J, Quiles F, Salinas M, Velasco A, Teulé A, Brunet J, Blanco I, Capellá G, Lázaro C.

Breast Cancer Res Treat. 2012 Apr;132(3):979-92. doi: 10.1007/s10549-011-1661-5. Epub 2011 Jul 7.

PMID:
21735045
9.

Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.

Rodriguez-Nieto S, Cañada A, Pros E, Pinto AI, Torres-Lanzas J, Lopez-Rios F, Sanchez-Verde L, Pisano DG, Sanchez-Cespedes M.

Hum Mutat. 2011 Feb;32(2):E1999-2017. doi: 10.1002/humu.21415. Epub 2010 Dec 7.

PMID:
21280140
10.

Dissecting loss of heterozygosity (LOH) in neurofibromatosis type 1-associated neurofibromas: Importance of copy neutral LOH.

Garcia-Linares C, Fernández-Rodríguez J, Terribas E, Mercadé J, Pros E, Benito L, Benavente Y, Capellà G, Ravella A, Blanco I, Kehrer-Sawatzki H, Lázaro C, Serra E.

Hum Mutat. 2011 Jan;32(1):78-90. doi: 10.1002/humu.21387.

11.

Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment.

Pros E, Fernández-Rodríguez J, Benito L, Ravella A, Capellá G, Blanco I, Serra E, Lázaro C.

Eur J Hum Genet. 2010 May;18(5):614-7. doi: 10.1038/ejhg.2009.212. Epub 2009 Nov 25.

12.

Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations.

Pros E, Fernández-Rodríguez J, Canet B, Benito L, Sánchez A, Benavides A, Ramos FJ, López-Ariztegui MA, Capellá G, Blanco I, Serra E, Lázaro C.

Hum Mutat. 2009 Mar;30(3):454-62. doi: 10.1002/humu.20933.

PMID:
19241459
13.

Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations.

Pros E, Gómez C, Martín T, Fábregas P, Serra E, Lázaro C.

Hum Mutat. 2008 Sep;29(9):E173-93. doi: 10.1002/humu.20826.

PMID:
18546366
14.

Tumor LOH analysis provides reliable linkage information for prenatal genetic testing of sporadic NF1 patients.

Serra E, Pros E, García C, López E, Gili ML, Gómez C, Ravella A, Capellá G, Blanco I, Lázaro C.

Genes Chromosomes Cancer. 2007 Sep;46(9):820-7.

PMID:
17563086
15.

NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.

Pros E, Larriba S, López E, Ravella A, Gili ML, Kruyer H, Valls J, Serra E, Lázaro C.

Hum Mutat. 2006 Nov;27(11):1104-14.

PMID:
16937374
16.

Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.

Ars E, Kruyer H, Morell M, Pros E, Serra E, Ravella A, Estivill X, Lázaro C.

J Med Genet. 2003 Jun;40(6):e82. No abstract available.

Supplemental Content

Support Center